PharmaShots | Incisive News in 3 Shots

Subscribe Now

Pembrolizumab

Merck Enters in Third Clinical Trial Collaboration with Adagene to Advance ADG106 + Keytruda (pembrolizumab) for Solid Tumors and Hematological Malignancies

Merck Enters in Third Clinical Trial Collaboration with Adagene to Advance ADG106 + Keytruda (pembrolizumab) for Solid Tumors and...

August 19, 2021

$Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Relapsed or Refractory Classical Hodgkin Lymphoma$

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Relapsed or Refractory Classical Hodgkin Lymphoma

October 16, 2020

Linnaeus Reports First Patients Dosing with LNS8801 + Keytruda (pembrolizumab) in P-I/II Study for Advanced Cancer

Linnaeus Reports First Patients Dosing with LNS8801 + Keytruda (pembrolizumab) in P-I/II Study for Advanced Cancer

October 14, 2020

Neuclone Discloses Two Biosimilars Referencing Opdivo (nivolumab) and Keytruda (pembrolizumab)

Neuclone Discloses Two Biosimilars Referencing Opdivo (nivolumab) and Keytruda (pembrolizumab)

September 1, 2020

Merck's Keytruda (pembrolizumab) Receives Two New PMDA's Approvals in Japan

Merck's Keytruda (pembrolizumab) Receives Two New PMDA's Approvals in Japan

August 25, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us